NovMetaPharma Co., Ltd.

A229500

KR7229500004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 23/06/2024 BST			5-day change	1st Jan Change
7,250 ^KRW	-0.68%		-10.27%	-64.63%

05-27	NovMetaPharma Co., Ltd. cancelled the acquisition of SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction.	CI
2023	NovMetaPharma Co., Ltd. agreed to acquire SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction	CI

NovMetaPharma Co., Ltd. announced that it has received KRW 4.511234288 billion in funding from Intellectual Discovery Co., Ltd.

April 18, 2019

On April 19, 2019, NovMetaPharma Co., Ltd. (XKON:A229500) closed the transaction.

Latest news about NovMetaPharma Co., Ltd.

NovMetaPharma Co., Ltd. cancelled the acquisition of SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction.	05-26	CI
NovMetaPharma Co., Ltd. agreed to acquire SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction	26/07/23	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 6.99999258 billion in funding from BNC Korea Co., Ltd.	28/06/23	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 6.99999258 billion in funding from BNC Korea Co., Ltd.	20/06/23	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 3.299969948 billion in funding from Road Jeilho Bio Private Equity Joint Venture Company	28/03/23	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 3.299969948 billion in funding from Road Jeilho Bio Private Equity Joint Venture Company and other investors	06/03/23	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 3.8000182 billion in funding from Heungkuk Life Insurance Co., Ltd.	18/11/21	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 3.8000182 billion in funding from Heungkuk Life Insurance Co., Ltd.	10/11/21	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 3 billion in funding	19/08/21	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 3 billion in funding	17/08/21	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 4.511234288 billion in funding from Intellectual Discovery Co., Ltd.	18/04/19	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 4.511234288 billion in funding from Intellectual Discovery Co., Ltd.	07/04/19	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 10.22 billion in funding from KMH Co. Ltd., Whale Investment and other investors	05/12/17	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 10.22 billion in funding from KMH Co. Ltd., Whale Investment and other investors	04/12/17	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 1.86 billion in funding	24/08/17	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 1.86 billion in funding	23/08/17	CI

NovMetaPharma Co., Ltd. is a Korea-based company mainly engaged in the development and sale of pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment is involved in the development and sale of diabetes treatment, obesity treatment, osteoporosis treatment, alzheimer's disease treatment, and autoimmune enhancers. The Health Functional Food segment is engaged in the manufacturing and sale of health functional food related to blood sugar, prostate health, comprehensive minerals, and cognitive improvement. It also produces and sells vinegar drinks. The Company distributes its products within the domestic market and to overseas markets, including America and China.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NOVMETAPHARMA CO., LTD.	-64.63%	45.42M
VERTEX PHARMACEUTICALS INCORPORATED	+16.45%	122B
REGENERON PHARMACEUTICALS, INC.	+21.96%	116B
ARGENX SE	+24.75%	27.03B
BIONTECH SE	-20.05%	20.36B
BEIGENE, LTD.	-16.28%	15.91B
GENMAB A/S	-16.96%	16.43B
WUXI APPTEC CO., LTD.	-44.35%	15.6B
SAREPTA THERAPEUTICS, INC.	+63.91%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+2.52%	13.59B

Bio Therapeutic Drugs